IDEAYA Biosciences (NASDAQ:IDYA) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of IDEAYA Biosciences (NASDAQ:IDYA) from a sell rating to a hold rating in a research note published on Friday.

Other equities analysts have also issued reports about the stock. JMP Securities started coverage on shares of IDEAYA Biosciences in a research report on Thursday, September 4th. They set a “market outperform” rating and a $41.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of IDEAYA Biosciences in a research report on Saturday, September 27th. The Goldman Sachs Group raised shares of IDEAYA Biosciences to a “hold” rating and set a $25.00 price target for the company in a research report on Thursday, July 10th. Oppenheimer set a $36.00 price target on shares of IDEAYA Biosciences and gave the stock an “outperform” rating in a research report on Monday, September 8th. Finally, Stephens reissued an “overweight” rating and set a $45.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, September 9th. Fourteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, IDEAYA Biosciences has an average rating of “Moderate Buy” and an average price target of $43.36.

IDEAYA Biosciences Stock Up 1.6%

Shares of IDEAYA Biosciences stock opened at $27.64 on Friday. The firm has a market capitalization of $2.42 billion, a P/E ratio of -7.29 and a beta of 0.14. The company has a 50 day moving average price of $25.04 and a 200 day moving average price of $21.48. IDEAYA Biosciences has a 52 week low of $13.45 and a 52 week high of $32.67.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The company had revenue of $6.00 million for the quarter, compared to analysts’ expectations of $3.48 million. The firm’s revenue was up NaN% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.68) earnings per share. As a group, research analysts anticipate that IDEAYA Biosciences will post -3.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. CWM LLC boosted its position in shares of IDEAYA Biosciences by 325.7% during the 1st quarter. CWM LLC now owns 2,371 shares of the company’s stock valued at $39,000 after acquiring an additional 1,814 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in shares of IDEAYA Biosciences by 180.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company’s stock valued at $39,000 after acquiring an additional 1,546 shares during the last quarter. Signaturefd LLC boosted its position in shares of IDEAYA Biosciences by 374.8% during the 1st quarter. Signaturefd LLC now owns 2,877 shares of the company’s stock valued at $47,000 after acquiring an additional 2,271 shares during the last quarter. Elevation Point Wealth Partners LLC acquired a new position in shares of IDEAYA Biosciences during the 2nd quarter valued at about $61,000. Finally, Daiwa Securities Group Inc. boosted its position in shares of IDEAYA Biosciences by 16.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock valued at $66,000 after acquiring an additional 436 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.